Home > Clinical Trials
Check All Search

Saved trials

ACTIVE_NOT_RECRUITING
NCT03523585
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
608 Enrollment(s)
227 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
RECRUITING
NCT07015697
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
76 Enrollment(s)
13 Study location(s)
INTERVENTIONAL (PHASE1)
Recurrent or Metastatic Solid Tumors
RECRUITING
NCT04686305
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
244 Enrollment(s)
86 Study location(s)
INTERVENTIONAL (PHASE1)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ACTIVE_NOT_RECRUITING
NCT04784715
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
1,157 Enrollment(s)
283 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer; HER2-positive; Metastatic
RECRUITING
NCT05408845
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
146 Enrollment(s)
143 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Salivary Gland Carcinoma


Recurrent Salivary Gland Carcinoma


Stage III Major Salivary Gland Cancer AJCC v8


Stage IV Major Salivary Gland Cancer AJCC v8


Unresectable Salivary Gland Carcinoma
ACTIVE_NOT_RECRUITING
NCT04704934
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
490 Enrollment(s)
156 Study location(s)
INTERVENTIONAL (PHASE3)
Gastric Cancer, Adenocarcinoma


Gastroesophageal Junction Adenocarcinoma
RECRUITING
NCT04553770
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
88 Enrollment(s)
9 Study location(s)
INTERVENTIONAL (PHASE2)
Early-stage Breast Cancer


Hormone Receptor Positive Breast Carcinoma


Invasive Breast Cancer


Stage II Breast Cancer


Stage IIA Breast Cancer


Stage IIB Breast Cancer


Stage III Breast Cancer
RECRUITING
NCT05681702
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
90 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Artery Disease